# US 2026/0224610 A1 · A bioactive poly(lactic-co-glycolic acid) (plga) material, related printed structure and related methods thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0224610 A1
- Document ID: US20260224610A1
- Status: Published application
- Kind: A1
- Application number: 19/159,743
- Filed: 2024-02-27
- Published: 2026-08-06
- Earliest claimed: 2023-02-27
- Assignees: Agency for Science, Technology and Research; Singapore Health Services Pte Ltd
- Applicants: Agency for Science, Technology and Research; Singapore Health Services Pte Ltd
- Inventors: Mohammad Asyraf Bin ABBAS; Peili TEO; Yew Chin TEO; Eun Ju PARK; Jiayi GUO; Wan Loong James MOK
- Web page: https://patentgrep.com/patent/US20260224610A1

## CPC

- A61K 31/765: Polymers containing oxygen
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61L 27/18: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
- A61L 27/56: Porous materials, {e.g. foams or sponges}
- A61L 27/60: Materials for use in artificial skin
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- B29C 64/118: using filamentary material being melted, e.g. fused deposition modelling [FDM]
- B33Y 70/00: Materials specially adapted for additive manufacturing
- B33Y 80/00: Products made by additive manufacturing
- C08G 63/664: derived from hydroxy carboxylic acids
- C08G 63/6852: {derived from hydroxy carboxylic acids}
- C08L 67/04: Polyesters derived from hydroxycarboxylic acids, e.g. lactones (C08L67/06 takes precedence)
- B33Y 10/00: Processes of additive manufacturing
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B29C: SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING (making preforms B29B11/00; making laminated products by combining previously unconnected layers which become one product whose layers will remain together B32B37/00 - B32B41/00)
- B33Y: ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- C08G: MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08L: COMPOSITIONS OF MACROMOLECULAR COMPOUNDS (compositions based on polymerisable monomers C08F, C08G; artificial filaments or fibres D01F; textile treating compositions D06)

## Abstract

There is provided a regenerative material for treatment of wounds, the material comprising: (i) a base poly(lactic-co-glycolic acid) (PLGA); (ii) a bioactive poly(lactic-co-glycolic acid) (PLGA) copolymer; and (iii) pores patterned on said material. Also provided are a medical device comprising said regenerative material, medical uses of said regenerative material, and a method of preparing said regenerative material.

## Claims

### Claim 1

A regenerative material for treatment of wounds, the material comprising:
(i) a base poly(lactic-co-glycolic acid) (PLGA);
(ii) a bioactive poly(lactic-co-glycolic acid) (PLGA) copolymer; and
(iii) pores patterned on said material.

### Claim 2 (depends on 1)

The regenerative material of claim 1, wherein each pore comprises a polygonal shape.

### Claim 3 (depends on 1)

The regenerative material of claim 1, wherein each pore has a minimum circumscribed circle diameter of at least 100 μm.

### Claim 4 (depends on 1)

The regenerative material of claim 1, wherein the distance between the pores is from 100 μm to 300 μm.

### Claim 5 (depends on 1)

The regenerative material of claim 1, wherein the material comprises a buffer zone surrounding the pores.

### Claim 6 (depends on 1)

The regenerative material of claim 1, wherein the material has an infill density of from 70% to 100%.

### Claim 7 (depends on 1)

The regenerative material of claim 1, wherein the ratio of the (i) base PLGA to (ii) bioactive PLGA copolymer present in the material is from about 60.0-99.9:0.1-40.0.

### Claim 8 (depends on 1)

The regenerative material of claim 1, wherein the material comprises from 60 wt % to 99.9 wt % of the base PLGA.

### Claim 9 (depends on 1)

The regenerative material of claim 1, wherein the material comprises from 0.1 wt % to 40 wt % of the bioactive PLGA copolymer.

### Claim 10 (depends on 1)

The regenerative material of claim 1, wherein the material comprises a three-dimensional (3D) printed structure or part.

### Claim 11 (depends on 1)

The regenerative material of claim 1, wherein the bioactive PLGA copolymer comprises a bioactive PLGA copolymer with a poly(norbornene-dicarboximide) backbone having one or more repeating units represented by general formula (I) and one or more repeating units represented by general formula (II):
wherein
R1 is selected from a single bond, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxyalkyl, optionally substituted alkylcarbonyl or optionally substituted alkylcarbonylalkyl;
R2 is optionally substituted alkyl;
R3 is selected from H, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl;
L is heteroalkylene;
X comprises a bioactive moiety selected from the group consisting of proteins, peptides, oligopeptides, carbohydrates, oligosaccharides, sugar, collagen, hyaluronic acid, therapeutic/drug molecules and derivatives thereof;
Z1 and Z2 are each independently selected from CRaRb, O, NRc, SiRaRb, PRa or S, wherein Ra, Rb and Rc are each independently selected from the group consisting of H, optionally substituted alkyl, optionally substituted alkenyl and optionally substituted alkynyl;
p
≥
1
;
and
q
≥
1.

### Claim 12 (depends on 1)

The regenerative material of claim 1, wherein X is selected from the group consisting of RGD, SRGDS, RGDS, A5G81 (AGQWHRVSVRWGC), SVVYGLR, (IRIK)2, (IKKI)3, heparin oligosaccharide DP8, DP10, DP12, DP14, DP16, DGEA, (PHypG)n type sequence, (PGHyp)n type sequence, (HypGP)n type sequence, (HypPG)n type sequence, (GHypP)n type sequence, (GPHyp)n type sequence, hyaluronic acid and combinations thereof.

### Claim 13 (depends on 1)

The regenerative material of claim 1, wherein the regenerative material is obtained by the method comprising:
(i) producing a bioactive PLGA filament; and
(ii) printing a bioactive PLGA material from the bioactive PLGA filament according to a design model to obtain a printed structure or part with pores patterned thereon.

### Claim 14 (depends on 13)

The regenerative material according to claim 13, wherein the step (i) of producing a bioactive PLGA filament comprises:
(i-a) providing a base PLGA powder and a bioactive PLGA copolymer;
(i-b) mixing the base PLGA powder with the bioactive PLGA copolymer to obtain a bioactive PLGA formulation; and
(i-c) extruding a bioactive PLGA filament from the formulation.

### Claim 15 (depends on 13)

The regenerative material according to claim 13, wherein the step (ii) of printing a bioactive PLGA material from the bioactive PLGA filament comprises:
(ii-a) feeding the bioactive PLGA filament into a printing apparatus;
(ii-b) applying heat to the bioactive PLGA filament to obtain a molten form of the bioactive PLGA; and
(ii-c) depositing the molten bioactive PLGA on a print bed to form a printed part or structure.

### Claim 16 (depends on 1)

The regenerative material of claim 1 for use in medicine.

### Claim at position 17

-22. (canceled)

### Claim 23 (depends on 1)

A method of stimulating skin and/or tissue regeneration in a subject in need thereof,
optionally wherein the method comprises a method of treating a wound,
optionally wherein the method comprises a method of controlling and/or reducing inflammation in a subject in need thereof,
wherein the method comprising applying the regenerative material of claim 1 to a body, a wound, and/or a body part of the subject in need thereof.

### Claim at position 19

-25. (canceled)

### Claim 26 (depends on 23)

The method of claim 23, wherein the wound is selected from the group consisting of acute wounds, burns, incisions, excisions, superficial wounds, partial thickness wounds, full thickness wounds, chronic wounds, slow healing wounds, pressure sores, venous ulcers, diabetic ulcers, foot ulcers, bed sores and combinations thereof.

### Claim 27 (depends on 1)

A medical device comprising the regenerative material of claim 1.

### Claim 28 (depends on 27)

The medical device according to claim 27, wherein the medical device is selected from the group consisting of dermal template, dermal regeneration template, skin scaffold, wound care product, wound dressing, personal care product, beauty product and combinations thereof.
